Stay updated with breaking news from Lpcn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report released on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock. Lipocine Price Performance LPCN opened at $2.47 on Friday. The business’s 50-day moving average is $2.78 and its two-hundred day moving average is $3.90. Lipocine […]
StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research note released on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock. Lipocine Price Performance Shares of NASDAQ LPCN opened at $2.51 on Friday. The company has a 50-day moving average price of $2.81 and a […]
By Emon Reiser Lipocine said the results of its Phase 2 study evaluating LPCN 1148, a treatment to manage decompensated cirrhosis, will be presented at the...
StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Lipocine Stock Performance Shares of Lipocine stock opened at $2.79 on Friday. The stock has a 50-day moving average price of $3.66 and a […]
StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a report published on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Lipocine Price Performance Lipocine stock opened at $2.96 on Friday. The company has a market cap of $15.75 million, a price-to-earnings ratio of -1.24 and a […]